Exelixis Inc (NASDAQ: EXEL)’s stock price has dropped by -1.19 in relation to previous closing price of 33.70. Nevertheless, the company has seen a loss of -0.54% in its stock price over the last five trading days. zacks.com reported 2024-12-25 that Investors with an interest in Medical – Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors?
Is It Worth Investing in Exelixis Inc (NASDAQ: EXEL) Right Now?
The price-to-earnings ratio for Exelixis Inc (NASDAQ: EXEL) is above average at 21.22x. The 36-month beta value for EXEL is also noteworthy at 0.53. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 5 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EXEL is 278.50M, and at present, short sellers hold a 2.63% of that float. The average trading volume of EXEL on January 01, 2025 was 2.18M shares.
EXEL’s Market Performance
EXEL’s stock has seen a -0.54% decrease for the week, with a -8.67% drop in the past month and a 26.62% gain in the past quarter. The volatility ratio for the week is 1.70%, and the volatility levels for the past 30 days are at 2.14% for Exelixis Inc The simple moving average for the last 20 days is -3.82% for EXEL’s stock, with a simple moving average of 26.20% for the last 200 days.
Analysts’ Opinion of EXEL
Many brokerage firms have already submitted their reports for EXEL stocks, with BMO Capital Markets repeating the rating for EXEL by listing it as a “Market Perform.” The predicted price for EXEL in the upcoming period, according to BMO Capital Markets is $40 based on the research report published on December 20, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see EXEL reach a price target of $39, previously predicting the price at $35. The rating they have provided for EXEL stocks is “Neutral” according to the report published on December 17th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to EXEL, setting the target price at $34 in the report published on October 16th of the previous year.
EXEL Trading at -2.02% from the 50-Day Moving Average
After a stumble in the market that brought EXEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.93% of loss for the given period.
Volatility was left at 2.14%, however, over the last 30 days, the volatility rate increased by 1.70%, as shares sank -6.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.22% upper at present.
During the last 5 trading sessions, EXEL fell by -0.54%, which changed the moving average for the period of 200-days by +44.91% in comparison to the 20-day moving average, which settled at $34.62. In addition, Exelixis Inc saw 38.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EXEL starting from Hessekiel Jeffrey, who sale 60,000 shares at the price of $36.67 back on Nov 29 ’24. After this action, Hessekiel Jeffrey now owns 486,059 shares of Exelixis Inc, valued at $2,200,200 using the latest closing price.
JEFFREY HESSEKIEL, the Officer of Exelixis Inc, proposed sale 60,000 shares at $36.67 during a trade that took place back on Nov 29 ’24, which means that JEFFREY HESSEKIEL is holding shares at $2,200,230 based on the most recent closing price.
Stock Fundamentals for EXEL
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.96 for the gross margin
The net margin for Exelixis Inc stands at 0.22. The total capital return value is set at 0.2. Equity return is now at value 20.20, with 15.73 for asset returns.
Currently, EBITDA for the company is 196.6 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 4.54. The receivables turnover for the company is 7.72for trailing twelve months and the total asset turnover is 0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.93.
Conclusion
In summary, Exelixis Inc (EXEL) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
